Shopify on Track for Highest Close Since March 2022 — Data Talk
Shopify, Inc. Class A (SHOP) is currently at $73.26, up $2.91 or 4.13%
--Would be highest close since March 29, 2022, when it closed at $74.40
--On pace for largest percent increase since Nov. 14, 2023, when it rose 5.1%
--Currently up five of the past six days
--Up 55.24% month-to-date; on pace for best month on record (Based on available data back to May 21, 2015)
--Up 111.06% year-to-date; on pace for best year since 2020, when it rose 184.71%
--Down 56.67% from its all-time closing high of $169.06 on Nov. 19, 2021
--Up 92.63% from 52 weeks ago (Nov. 28, 2022), when it closed at $38.03
--Would be a new 52-week closing high
--Up 124.44% from its 52-week closing low of $32.64 on Dec. 28, 2022
--Traded as high as $74.03; highest intraday level since April 5, 2022, when it hit $74.13
--Up 5.23% at today's intraday high; largest intraday percent increase since Nov. 14, 2023, when it rose as much as 6.14%
All data as of 10:56:34 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 27, 2023 11:13 ET (16:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track